Patent intelligence · US
US 6313163
2,4-pentadienoic acid derivatives having retinoid-like biological activity
2,4-pentadienoic acid derivatives having retinoid-like biological activity
Patent details — US 6313163
- Jurisdiction
- US
- Status
- expired
- Grant date
- Nov 6, 2001
- Expiration
- Nov 1, 2021
- Applicant
- ALLERGEN SALES INC [US]
- CPC classes
- A61K 31/ 20 A I, A61K 31/ 23 A I, A61K 31/ 35 A I, A61K 31/ 38 A I
Quick answer
US 6313163 (2,4-pentadienoic acid derivatives having retinoid-like biological activity) is held by ALLERGEN SALES INC [US]. Status: expired. Granted Nov 6, 2001. Expires Nov 1, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALLERGEN SALES INC [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 20 A I, A61K 31/ 23 A I, A61K 31/ 35 A I, A61K 31/ 38 A I, A61K 31/ 47 A I, A61K/3120
More from ALLERGEN SALES INC [US]
Related pharmaceutical patents in our USPTO index.
-
CN 112638413
Oral immunotherapy unit dose dispensing systems and methods
granted -
WO 2015187736
FORMULATIONS PLACEBO ET UTILISATIONS DE CELLES-CI
granted -
US 2014356438
PERIPHERALLY ADMINISTERED VISCOUS FORMULATIONS
granted -
US 2014271721
PEANUT FORMULATIONS AND USES THEREOF
granted -
US 2014271836
MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION
granted -
US 2013209398
CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS AND METHODS OF USE
granted -
CA 2849366
COMPOSITIONS ET PROCEDES POUR TRAITER LA PRESBYTIE, L'HYPERMETROPIE LEGERE ET L'ASTIGMATISME IRREGULIER
granted -
US 2012003230
SUSTAINED RELEASE DRUG DELIVERY SYSTEMS COMPRISING A WATER SOLUBLE THERAPEUTIC AGENT AND A RELEASE MODIFIER
granted
Frequently asked questions
What is US patent 6313163?
US 6313163 (2,4-pentadienoic acid derivatives having retinoid-like biological activity) is held by ALLERGEN SALES INC [US]. Status: expired. Granted Nov 6, 2001. Expires Nov 1, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6313163?
ALLERGEN SALES INC [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.
When does US 6313163 expire?
Our index shows an expiration date of Nov 1, 2021 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.